Targacept, Inc. Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer's Disease

Published: Apr 29, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it has completed recruitment of patients in the Phase 2b study of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. Targacept expects to report top-line results from the study in mid-2014. TC-1734 is a modulator of the alpha4beta2 neuronal nicotinic receptor subtype.

Help employers find you! Check out all the jobs and post your resume.

Back to news